SCHEMBL1477524

SCHEMBL1477524

COc1cc(F)cc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
EPAS1 Q99814 10/20 0.41
AHR P35869 1/20 0.39
NQO2 P16083 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31405023 1.00 ALDH1A1 (0.46) ALDH1A1EPAS1AHRNQO2TAAR1
SCHEMBL10875538 0.84 LTA4H (0.45) EPAS1AHR
SCHEMBL186502 0.82 ALDH1A1 (0.59) ALDH1A1NQO2TAAR1
SCHEMBL168353 0.82 ALDH1A1 (0.69) ALDH1A1AHRNQO2TAAR1
SCHEMBL21263 0.82 ALDH1A1 (0.69) ALDH1A1AHRNQO2
SCHEMBL811578 0.82 ALDH1A1 (0.59) ALDH1A1AHR
SCHEMBL5178645 0.80 NFE2L2 (0.54) ALDH1A1NQO2
SCHEMBL1816933 0.79 ALDH1A1 (0.65) ALDH1A1AHRNQO2
SCHEMBL28897626 0.77 ALDH1A1 (0.50) ALDH1A1EPAS1
SCHEMBL6832377 0.76 MAPT (0.41) EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090269674-A1 ELECTROLYTE FOR LITHIUM BATTERY AND LITHIUM BATTERY COMPRISING SAME SAMSUNG SDI CO., LTD. (KR) 2009-10-29 US claimed
CN-100521357-C Electrolyte for lithium battery and lithium battery containing the same SAMSUNG SDI CO LTD (KR) 2009-07-29 CN claimed
CN-100461525-C Non aqueous electrolyte and lithium secondary cell using it SAMSUNG SDI CO LTD (KR) 2009-02-11 CN claimed
US-20070212614-A1 Electrolyte for lithium battery and lithium battery comprising same SAMSUNG SDI CO., LTD. (KR) 2007-09-13 US claimed
US-7223500-B2 Non-aqueous electrolyte and a lithium secondary battery comprising the same SAMSUNG SDI CO., LTD. (KR) 2007-05-29 US claimed
US-20040197667-A1 Non-aqueous electrolyte and a lithium secondary battery comprising the same SAMSUNG SDI CO., LTD. (KR) 2004-10-07 US claimed
EP-1463143-A2 A non-aqoeous electrolyte and a lithium secondary battery comprising the same Samsung SDI Co., Ltd. (KR) 2004-09-29 EP claimed
CN-1532986-A Non aqueous electrolyte and lithium secondary cell using it ����SDI��ʽ���� 2004-09-29 CN claimed
CN-1449070-A Electrolyte for lithium battery and lithium battery containing the same SAMSUNG SDI CO LTD (KR) 2003-10-15 CN claimed
US-20030190529-A1 Electrolyte for lithium battery and lithium battery comprising same SAMSUNG SDI CO., LTD. (KR) 2003-10-09 US claimed
US-11071736-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION 2021-07-27 US disclosed
US-11071736-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION 2021-07-27 US disclosed
US-10588909-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2020-03-17 US disclosed
US-20190002448-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2019-01-03 US disclosed
EP-2785714-B1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORP (TW) 2018-11-21 EP disclosed
US-20040197667-A1 Non-aqueous electrolyte and a lithium secondary battery comprising the same SAMSUNG SDI CO., LTD. (KR) 2004-10-07 US disclosed
EP-1463143-A2 A non-aqoeous electrolyte and a lithium secondary battery comprising the same Samsung SDI Co., Ltd. (KR) 2004-09-29 EP disclosed
CN-1532986-A Non aqueous electrolyte and lithium secondary cell using it ����SDI��ʽ���� 2004-09-29 CN disclosed
CN-1449070-A Electrolyte for lithium battery and lithium battery containing the same SAMSUNG SDI CO LTD (KR) 2003-10-15 CN disclosed
US-20030190529-A1 Electrolyte for lithium battery and lithium battery comprising same SAMSUNG SDI CO., LTD. (KR) 2003-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002448-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BCL3 ALDH1A1 530/4885EPAS1 3090/4885AHR 289/4885
US-10588909-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 ALDH1A1 3121/4885EPAS1 102/4885AHR 3191/4885
US-11071736-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 ALDH1A1 3121/4885EPAS1 102/4885AHR 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.